Understanding how very long chain fatty acids affect multiple myeloma treatment
Regulation and Function of Very Long Chain Fatty Acid Biosynthesis in Multiple Myeloma
This study is looking at how certain fatty acids might help improve treatment for multiple myeloma by affecting how cancer cells respond to stress, especially when using a common medication called bortezomib, to find better ways to help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10893301 on NIH RePORTER |
What this research studies
This research investigates the role of very long chain fatty acids in the treatment of multiple myeloma, a type of blood cancer. It focuses on how these fatty acids influence the stress response of cancer cells, particularly in relation to a common treatment called bortezomib. By exploring the mechanisms that regulate the endoplasmic reticulum's function in these cells, the study aims to identify new therapeutic targets that could improve treatment outcomes for patients. The research involves laboratory experiments to analyze the effects of specific enzymes and fatty acids on cancer cell viability and treatment resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multiple myeloma, particularly those who have shown resistance to current treatments.
Not a fit: Patients with other types of blood cancers or those not diagnosed with multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the effectiveness of existing therapies for multiple myeloma.
How similar studies have performed: Previous research has shown promising results in targeting endoplasmic reticulum stress in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Nikiforov, Mikhail — Duke University
- Study coordinator: Nikiforov, Mikhail
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.